IDYA (STOCKS)
IDEAYA Biosciences, Inc. Common Stock
$31.520000
-0.380000 (-1.19%)
Prev close: $31.900000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Yujiro S. Hata
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,759.74M
- Employees
- 131
- P/E (TTM)
- -16.99
- P/B (TTM)
- 2.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
13
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$1.33 | $-0.56 | +1.8857 | +339.34% |
|
Jun 2025 (Q2)
|
$-0.88 | $-0.81 | -0.0750 | -9.32% |
|
Mar 2025 (Q1)
|
$-0.82 | $-0.67 | -0.1453 | -21.54% |
|
Dec 2024 (Q4)
|
$-1.49 | $-0.65 | -0.8374 | -128.32% |
Financial Statements
| Revenues | $214.83M |
| Nonoperating Income/Loss | $48.14M |
| Operating Expenses | $423.72M |
| Depreciation and Amortization | $2.60M |
| Research and Development | $368.29M |
| Other Operating Expenses | $52.83M |
| Operating Income/Loss | -$208.88M |
| Income/Loss From Continuing Operations After Tax | -$160.74M |
| Income/Loss From Continuing Operations Before Tax | -$160.74M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$160.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$160.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$160.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.89 |
| Diluted Earnings Per Share | -$1.89 |
| Basic Average Shares | 90,353,736 |
| Diluted Average Shares | 90,353,736 |
| Assets | $1.19B |
| Current Assets | $802.66M |
| Noncurrent Assets | $382.48M |
| Fixed Assets | $8.17M |
| Other Non-current Assets | $374.31M |
| Liabilities | $93.10M |
| Current Liabilities | $64.51M |
| Accounts Payable | $18.43M |
| Wages | $9.38M |
| Other Current Liabilities | $36.69M |
| Noncurrent Liabilities | $28.59M |
| Equity | $1.09B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.09B |
| Liabilities And Equity | $1.19B |
| Net Cash Flow From Operating Activities | -$102.26M |
| Net Cash Flow From Operating Activities, Continuing | -$102.26M |
| Net Cash Flow From Investing Activities | -$29.61M |
| Net Cash Flow From Investing Activities, Continuing | -$29.61M |
| Net Cash Flow From Financing Activities | $30.40M |
| Net Cash Flow From Financing Activities, Continuing | $30.40M |
| Net Cash Flow | -$101.46M |
| Net Cash Flow, Continuing | -$101.46M |
| Comprehensive Income/Loss | -$162.52M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$162.52M |
| Other Comprehensive Income/Loss | $117.46M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.78M |